| Literature DB >> 35734294 |
Ting-Yung Chang1,2,3,4, Chin-Yu Lin1,2,3, Yenn-Jiang Lin1,2,3, Cheng-I Wu1,2,3, Shih-Lin Chang1,2,3, Li-Wei Lo1,2,3, Yu-Feng Hu1,2,3, Fa-Po Chung1,2,3, Ta-Chuan Tuan1,2,3, Tze-Fan Chao1,2,3, Jo-Nan Liao1,2,3, Ling Kuo1,2,3, Chih-Min Liu1,2,3, Shih-Ann Chen1,2,3,5.
Abstract
Background: Catheter ablation is a current therapeutic approach for atrial fibrillation (AF). However, its efficacy for long-standing persistent AF remains suboptimal. Objective: The purpose of this study was to test the hypothesis that a panoramic mapping system (CARTOFINDER, Biosense Webster) can guide pulmonary vein (PV) isolation and additional potential AF drivers.Entities:
Keywords: Ablation; CARTOFINDER; Long-standing persistent atrial fibrillation; Outcome; Substrate modification
Year: 2022 PMID: 35734294 PMCID: PMC9207729 DOI: 10.1016/j.hroo.2022.04.003
Source DB: PubMed Journal: Heart Rhythm O2 ISSN: 2666-5018
Figure 1Enrollment of the study population. AF = atrial fibrillation; PV = pulmonary vein.
Figure 2Examples of CARTOFINDER-identified activities. A: Focal activity near the posterior antrum of the left superior pulmonary vein. B: Rotational activity near the posterior mitral isthmus.
Figure 3Comparison between the CARTOFINDER-guided approach and the conventional method of wide antral isolation. A: Fast anatomic mapping and CARTOFINDER mapping. B: Modified ablation line encircling the lesions identified by CARTOFINDER around the pulmonary vein antra. C: Bipolar voltage map during sinus rhythm after ablation guided by CARTOFINDER. D: Creation of electroanatomic geometry. E: Conventional wide antral isolation during atrial fibrillation. F: Bipolar voltage map during sinus rhythm after ablation by conventional wide antral isolation.
Baseline characteristics and demographics between the two groups with long-standing persistent AF
| Group 1 (n = 40) | Group 2 (n = 80) | ||
|---|---|---|---|
| Age (y) | 57.5 ± 9.3 | 56.5 ± 8.9 | .590 |
| BMI (kg/m2) | 25.2 ± 6.5 | 25.9 ± 2.5 | .489 |
| Male | 34 (85.0) | 73 (91.3) | .355 |
| Diabetes mellitus | 5 (12.5) | 7 (8.8) | .531 |
| CHF | 4 (10.0) | 10 (12.5) | .772 |
| Hypertension | 15 (37.5) | 38 (47.5) | .334 |
| CAD | 3 (7.5) | 7 (8.8) | 1 |
| Ischemic stroke | 3 (7.5) | 12 (15.0) | .380 |
| CHA₂DS₂-VASc score | 1.26 ± 1.2 | 1.06 ± 1.0 | .426 |
| AF duration (mo) | 39.7 ± 27 | 40.9 ± 26 | .758 |
| LDL (mg/dL) | 107 ± 30 | 106 ± 18 | .898 |
| LA diameter (mm) | 47.2 ± 5.1 | 45.9 ± 4.3 | .221 |
| Procedural time (min) | 219 ± 70 | 150 ± 49 | <.001 |
| Patients with PV CARTOFINDER-identified activity | 29 (72.5) | — | — |
| Termination of AF during PV isolation | 1 (2.5) | 3 (3.8) | .719 |
| Patients with non-PV trigger or CARTOFINDER-identified activity | 38 (95.0) | 15 (18.8) | <.001 |
| Termination of AF during non-PV atrial ablation | 2 (5.0) | — | — |
| Acute reconnection of PV | 2 (5.0) | 4 (5.0) | 1 |
| Additional ablation area of CARTOFINDER-identified activity around RPV antrum (cm2) | 0.53 ± 0.8 | — | — |
| Additional ablation area of CARTOFINDER-identified activity around LPV antrum (cm2) | 0.79 ± 1.4 | — | — |
| Complications | 1 (2.5) | 2 (2.5) | 1 |
| Tamponade | 0 (0) | 0 (0) | — |
| Pseudoaneurysm | 1 (2.5) | 2 (2.5) | — |
| Phrenic nerve injury | 0 (0) | 0 (0) | — |
| Amiodarone, before ablation | 22 (55.0) | 46 (51.7) | — |
| Amiodarone, after ablation | 14 (35.0) | 36 (45.0) | — |
| No. of AADs during follow-up | 1.1 ± 0.8 | 1.2 ± 0.6 | .517 |
| Recurrence of AF | 12 (30.0) | 56 (70.0) | <.001 |
| Recurrence of atrial flutter | 6 (15.0) | 20 (25.0) | .247 |
| Recurrence of atrial tachycardia | 0 (0) | 2 (2.5) | .552 |
Values are given as mean ± SD or n (%) unless otherwise indicated.
AAD = antiarrhythmic drug; AF = atrial fibrillation; BMI = body mass index; CAD = coronary artery disease; CHF = congestive heart failure; LA = left atrium; LDL = low-density lipoprotein; LPV = left pulmonary vein; PV = pulmonary vein; RPV = right pulmonary vein.
Figure 4Distribution of focal (F) and rotational (R) activities of long-standing persistent atrial fibrillation in group 1. The left atrium was divided into 11 regions: right superior pulmonary vein (RSPV), right inferior pulmonary vein (RIPV), left superior pulmonary vein (LSPV), left inferior pulmonary vein (LIPV), left atrial appendage (LAA), septum, anterior wall, roof, posterior wall, bottom, and lateral wall. The number and percentage of patients in group 1 with CARTOFINDER-identified focal/rotational activities in each region were calculated. For example, in group 1, 32 patients (80%) had focal activities and 2 patients (5%) had rotational activities in the LAA.
Figure 5Kaplan-Meier curves of recurrence after the index procedure during follow-up between the 2 groups. A: Recurrence of atrial fibrillation between group 1 (CARTOFINDER method) and group 2 (conventional method). B: Recurrence of atrial flutter between group 1 (CARTOFINDER method) and group 2 (conventional method). C: Recurrence of atrial tachycardia between group 1 (CARTOFINDER method) and group 2 (conventional method).
Comparison of factors between patients with/without recurrent AF and Cox proportional hazards regression analysis of AF recurrence after catheter ablation
| Without recurrent AF | With recurrent AF | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| (n = 52) | (n = 68) | 95% CI | 95% CI | ||||
| Age (y) | 57.2 ± 10.9 | 56.7 ± 7.5 | .768 | .975 | 0.976–1.024 | — | — |
| BMI (kg/m2) | 25.5 ± 5.8 | 23.8 ± 8.1 | .456 | .941 | 0.874–1.013 | — | — |
| Male | 45 (86.5) | 62 (91.2) | .555 | .648 | 0.525–2.816 | — | — |
| Diabetes mellitus | 4 (7.7) | 8 (11.8) | .550 | .260 | 0.729–3.219 | — | — |
| CHF | 7 (13.5) | 7 (10.3) | .775 | .360 | 0.316–1.518 | — | — |
| Hypertension | 17 (32.7) | 36 (52.9) | .041 | .161 | 0.873–2.269 | — | — |
| CAD | 4 (7.7) | 7 (10.3) | .755 | .184 | 0.777–3.732 | — | — |
| Ischemic stroke | 7 (13.5) | 8 (11.8) | .788 | .536 | 0.378–1.658 | — | — |
| CHA₂DS₂-VASc score | 1.17 ± 1.3 | 1.10 ± 1.0 | .747 | .678 | 0.777–1.178 | — | — |
| AF duration (mo) | 30.3 ± 30 | 45.9 ± 40 | .021 | .020 | 1.001–1.013 | .022 | 1.001–1.013 |
| LDL (mg/dL) | 106.9 ± 26 | 107.6 ± 21 | .936 | .661 | 0.969–1.051 | — | — |
| LA diameter (mm) | 46.1 ± 4.1 | 46.3 ± 4.9 | .779 | .514 | 0.963–1.078 | — | — |
| Group 1 | 28 (53.8) | 12 (17.6) | <.001 | .044 | 0.280–0.982 | .046 | 0.282–0.989 |
| Termination of AF during ablation | 3 (5.8) | 3 (4.4) | 1 | .876 | 0.343–3.504 | — | — |
| Acute reconnection of PV | 3 (5.8) | 3 (4.4) | 1 | .876 | 0.343–3.504 | — | — |
| Procedural time (min) | 193.9 ± 71 | 153.8 ± 54 | .005 | .223 | 0.979–1.005 | — | — |
| No. of AADs | 1.1 ± 0.7 | 1.2 ± 0.5 | .524 | .921 | 0.695–1.496 | — | — |
Values are given as mean ± SD or n (%) unless otherwise indicated.
CI = confidence interval; other abbreviations as in Table 1.